Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Ruth Perets, AACR 2022: Vibostolimab / Pembrolizumab Coformulation for the Treatment of Ovarian Cancer Naive to PD-1/PD-L1 Inhibitors

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: May 11th 2022

We were delighted to speak with Dr. Ruth Perets (Rambam Health Care Campus, Haifa, Israel) about the efficacy and safety findings of the phase 1 study comparing vibostolimab (vibo) plus pembrolizumab (pembro) given sequentially to the coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors.

The abstract ‘Safety and efficacy of vibostolimab (vibo) plus pembrolizumab (pembro) and coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors.’ (Abstract number CT180) was presented at AACR 2022, 8-13 April, 2022.

Questions

  1. What are the current unmet needs in the treatment of ovarian cancer in patients who are naive to PD-1/PD-L1 inhibitors? (0:30)
  2. What is the potential role of the anti-TIGIT antibody vibostolimab in ovarian cancer management? (1:19)
  3. How might the efficacy of vibostolimab differ if used in combination with pembrolizumab compared with as a coformulation with pembrolizumab? (2:28)
  4. What are the current findings of this ongoing phase 1 study of the vibostolimab/ pembrolizumab coformulation? (3:08)

Disclosures: Ruth Perets discloses consulting for MSD.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the AACR annual meeting 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup